Somnomed Limited · ASX:SOM
Somnomed — Investor Presentation (August 2019)
27 slides from Somnomed's investor presentation, Aug 21, 2019
Slide 1: Investor Presentation FY2019
For personal use only Investor Presentation FY2019
Slide 2: Disclaimer & Regulatory Disclosure
DISCLAIMER & REGULATORY DISCLOSURE For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Treatment focused, Technology driven
For personal use only Treatment focused Technology driven
Slide 4: For personal use only
1.Vision For personal use only 2.Market opportunity 3.Core strengths 4.The alternative 5.Summary FY19 6.Financials 7.Future horizons 8.Outlook and guidance FY20
Slide 5: Vision/Mission
Vision/Mission For personal use only Vision: SomnoMed will be a leader in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Mission: Advancing the adoption and acceptance of the treatment therapies by medical specialists, dentists, patients and insurer
Slide 6: Obstructive Sleep Apnea
SOMNOMED Obstructive Sleep Apnea For personal use only Obstructive sleep apnea is a disorder that occurs when a person’s breathing is interrupted during sleep because the airway becomes blocked 6 https://somnomed.com 6
Slide 7: Global market opportunity is large
SOMNOMED Global market opportunity is large For personal use only https://somnomed.com 7
Slide 8: OSA Market
OSA MARKET 1.36 billion patients globally suffer with OSA* For personal use only Affects 9% of women and 25% of men globally Large addressable markets: 54m mild OSA sufferers Moderate 26m mild OSA sufferers & severe OSA 23m mild OSA sufferers Mild OSA 936m patients 22m mild OSA sufferers * Benjafiel
Slide 9: The CPAP therapy dilemma
The CPAP therapy dilemma 50% of patients do not use CPAP after 6 months* For personal use only Clinical Insight “The findings are sobering. Our data suggest that despite numerous changes to machine and mask dynamics as well as behavioral interventions, CPAP adherence remains a severe problem for man
Slide 10: There is a high ceiling for COAT growth
SOMNOMED There is a high ceiling for COAT™ growth For personal use only Source: Reimbursement authorities / SomnoMed internal / gathered in-market knowledge https://somnomed.com 10
Slide 11: SomnoMed core strengths
SomnoMed core strengths For personal use only Leader in the oral appliance treatment of Obstructive Sleep Apnea Design and Manufacturing Sales and Service and innovation distribution support Traditional Titration methodology Strong market brand Technical support Digital done right Product range Dire
Slide 12: The patient preferred alternative
The patient preferred alternative For personal use only SomnoMed is the world leader in oral appliances with over 500,000 patients treated worldwide https://somnomed.com https://somnomed.com 12
Slide 13: FY2019 Summary
FY2019 Summary For personal use only SomnoMed’s core revenue growth +12% over prior year Cash on hand $8m and ahead of forecast, with long to $59m term banking facility now in place North America +11% Treated >500,000 patients world-wide Europe +13% First managed healthcare contract signed with larg
Slide 14: Financials: Revenue growth
Financials For personal use only Revenue growth https://somnomed.com https://somnomed.com 14
Slide 15: Core revenue growth by region
Financials For personal use only Core revenue growth by region https://somnomed.com https://somnomed.com 15
Slide 16: North America FY19 direct dental revenue growth by quarter
Financials For personal use only North America FY19 direct dental revenue % growth by quarter (in US$) https://somnomed.com https://somnomed.com 16
Slide 17: Europe FY19 revenue growth by market segment
Financials For personal use only Europe FY19 revenue % growth by market segment (in EURO) https://somnomed.com https://somnomed.com 17
Slide 18: Gross margins underpinned by strong MAS margin
Financials For personal use only Gross margins underpinned by strong MAS margin 40.0 0.4 34.7 35.0 3.2 31.1 30.0 Gross Profit (A$m) 25.0 20.0 15.0 10.0 5.0 - MAS Other Revenue Managed Care Core 87% margin 70% Gross 59% 4% 1 2 3 4 https://somnomed.com https://somnomed.com 18
Slide 19: Financials: EBITDA
Financials For personal use only EBITDA https://somnomed.com https://somnomed.com 19
Slide 20: Financial Summary - AUD $000's SomnoMed core
Financial Summary - AUD $000's SomnoMed core FY19 FY18* % For personal use only Revenue 58,892 52,394 12% Gross margin 34,572 31,856 9% Regional sales and marketing expenses (14,967) (13,789) 9% Regional administrative expenses (11,195) (9,381) 19% Operating profit before corporate, research and bus
Slide 21: Our future horizons
Our future horizons For personal use only Advancing treatment Positioning Technology and building “the patient’s driven the core alternative” https://somnomed.com https://somnomed.com 21
Slide 22: Advancing Treatment and building the core
Advancing Treatment and building the core For personal use only Launch of Relationship Digital SomnoDent bridge strength chain Avant™ Restore relationships with Unique digital manufacturing Improved comfort USA dentists platform to drive future Innovative design Build on medical growth relationships
Slide 23: Positioning "the patient's alternative"
Positioning “the patient’s alternative” For personal use only Redefining effective medical Drive patient outcomes with prescribers demand If you don’t use it, it doesn’t work Target specific mild and moderate Strongly position COAT™ as the patient profile through the Sleep alternative to CPAP 1. Com
Slide 24: Technology driven
Technology driven For personal use only Technology Connected Patient pathway bridge health management Exclusive software Use of immense database Upfront patient pathway platform connecting and AI to add value to both management and optimization medical specialists to medical and dental partners befo
Slide 25: FY20 Outlook and guidance
FY20 Outlook and guidance For personal use only Broadening the sales and marketing focus in all regions SomnoDent Avant™ launch Digital done right and next steps Reimbursement policy Horizon development Guidance: Revenues from $59m to between $67m and $69m (growth between 14% and 17%) EB
Slide 26: Treatment focused, Technology driven
For personal use only Treatment focused Technology driven
Slide 27: Contact
Contact For personal use only Chief Executive Officer : Mr Neil Verdal-Austin Chief Financial Officer : Mr Hervé Fiévet Address: 20 Clarke Street, Crow’s Nest, Sydney 2065 Telephone: 02 9467 0400 Website: www.somnomed.com